Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 ...

Researchers at Baylor College of Medicine and collaborating institutions used complementary approaches that integrate exome ...

DNA data saved: 23andMe co-founder Anne Wojcicki has bid $305 million through a nonprofit to acquire her bankrupt company, ...

If approved by the court, the 23andMe sale would put Anne Wojcicki back at the helm of the company she co-founded and previously attempted to take private.

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...